Glyn Ed­wards takes chair­man role at UK on­colyt­ic virus start­up emerg­ing out of stealth

On­colyt­ic virus­es — virus­es that can se­lec­tive­ly repli­cate in can­cer cells and kill them — have been steadi­ly at­tract­ing in­vest­ment and cu­rios­i­ty. How­ev­er, for the most part, those can­di­dates have not quite panned out to the ex­tent their back­ers hope.

But now, one new biotech claims it can ac­tu­al­ly meet that bar.

VacV Bio­ther­a­peu­tics emerged from stealth in the UK ear­ly Wednes­day morn­ing, helmed by chief founder and CSO Yao­he Wang and en­list­ing Glyn Ed­wards — the for­mer head at C. dif­fi­cile biotech Sum­mit Ther­a­peu­tics be­fore Bob Dug­gan took over in 2020 — as ex­ec­u­tive chair­man. Ed­wards tells End­points News that he got in­volved ear­li­er this year, back in June, as Wang was look­ing to set up a com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER